Payment overview · 2025
General Payments
$1,513.07
30 reported records · 9 companies
Healthcare provider profile · identity verified
Dae-Wook Kang, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAN JOSE, CA · NPI 1194741272
Verified facts
What the public records show
CMS Open Payments records show Dae-Wook Kang, MD received $1,513.07 in general payments during 2025 across 30 reported records.
Amgen Inc. accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Ozempic, Rybelsus, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Kerendia by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vemlidy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $278.28 | 18.4% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $251.21 | 16.6% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $210.28 | 13.9% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $183.93 | 12.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $168.34 | 11.1% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $144.70 | 9.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $136.15 | 9.0% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $124.81 | 8.2% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $15.37 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,513.07 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $251.21 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $183.93 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $168.34 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $153.29 | 3 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $144.70 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $144.70 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $136.50 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $136.15 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $124.81 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $60.42 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $11.16 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 160 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 106 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
160 | 43 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
106 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 871 | 266 |
| Amlodipine Besylate | Amlodipine Besylate | 637 | 205 |
| Losartan Potassium | Losartan Potassium | 529 | 170 |
| Metformin Hcl | Metformin Hcl | 488 | 144 |
| Pravastatin Sodium | Pravastatin Sodium | 307 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 296 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 255 | 84 |
| Omeprazole | Omeprazole | 232 | 89 |
| Alendronate Sodium | Alendronate Sodium | 206 | 64 |
| Gabapentin | Gabapentin | 187 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 183 | 54 |
| Lisinopril | Lisinopril | 175 | 55 |
| Farxiga | Dapagliflozin Propanediol | 160 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 160 | 50 |
| Nifedipine Er | Nifedipine | 153 | 43 |
| Simvastatin | Simvastatin | 133 | 37 |
| Jardiance | Empagliflozin | 132 | 41 |
| Vascepa | Icosapent Ethyl | 132 | 37 |
| Celecoxib | Celecoxib | 109 | 41 |
| Ozempic | Semaglutide | 106 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 30 |
| Azithromycin | Azithromycin | 95 | 69 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 36 |
| Acarbose | Acarbose | 90 | 43 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 86 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 23 |
| Montelukast Sodium | Montelukast Sodium | 80 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 23 |
| Mirtazapine | Mirtazapine | 68 | 23 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 65 | 17 |
| Furosemide | Furosemide | 64 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 21 |
| Famotidine | Famotidine | 62 | 32 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 60 | 43 |
| Finasteride | Finasteride | 60 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 20 |
| Eliquis | Apixaban | 57 | 20 |
| Trazodone Hcl | Trazodone Hcl | 56 | 25 |
| Icosapent Ethyl | Icosapent Ethyl | 54 | 21 |
| Ezetimibe | Ezetimibe | 48 | 16 |
| Allopurinol | Allopurinol | 47 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 46 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 39 |
| Creon | Lipase/Protease/Amylase | 42 | 19 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Myrbetriq | Mirabegron | 40 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 40 | suppressed |
| Atenolol | Atenolol | 39 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 39 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 38 | 12 |
| Metformin Hcl Er | Metformin Hcl | 37 | 13 |
| Prednisone | Prednisone | 36 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 29 |
| Lactulose | Lactulose | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 21 |
| Zenpep | Lipase/Protease/Amylase | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | 11 |
| Valsartan | Valsartan | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | 11 |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 16 |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 13 |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 21 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Kerendia | Finerenone | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | 13 |
| Potassium Chloride | Potassium Chloride | 20 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Irbesartan | Irbesartan | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Prolia | Denosumab | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Rayaldee | Calcifediol | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,513.07 · 30 records | Amgen Inc. | AIRSUPRA, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, FARXIGA, Flector, Kerendia, Licart, OTEZLA, Ozempic, REPATHA, Rybelsus, TZIELD, Tirosint, ZENPEP | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error